Podcasts about cardiac

What if one of the most powerful tools for improving your cardiovascular resilience was already built into your body—and completely free? In this science-forward solo episode, Darin dives into the fascinating physiology of breath holding and the mammalian dive response, an ancient survival mechanism humans share with seals, whales, and dolphins. Simply holding your breath triggers an extraordinary cascade inside the body: your heart rate slows, blood vessels constrict to preserve oxygen for vital organs, and your spleen contracts to release oxygen-rich red blood cells into circulation. Darin explores research on elite freedivers, Southeast Asian sea nomads, cardiac hypoxic resistance, and the remarkable ways the human body can adapt to repeated breath-hold training. But he also separates the evidence from the hype, explaining why breath holding alone isn't a miracle intervention and why some of the most promising benefits appear when hypoxic stress is combined with movement and resistance exercise. This episode is a reminder that some of the most extraordinary tools for improving human performance aren't expensive supplements or complicated technologies—they're capacities your body has possessed all along. What You'll Learn What happens inside your body the moment you hold your breath How the mammalian dive response slows your heart rate and redirects blood flow Why your spleen acts like a biological reservoir for oxygen-rich red blood cells How humans share this ancient survival mechanism with marine mammals Why Southeast Asian sea nomads developed remarkable adaptations for freediving How breath-hold training can amplify the body's natural dive response What researchers discovered when elite divers reached extraordinarily low blood oxygen levels How repeated training may create greater hypoxic resilience in the heart Why the long-term benefits of breath-hold training in everyday people are still being studied Why combining hypoxic stress with movement may be more powerful than breath holding alone Chapters 00:00:03 – Welcome to SuperLife 00:00:34 – Sponsor: Alkemis 00:03:26 – The incredible thing happening when you hold your breath 00:03:57 – The ancient survival program you share with dolphins and whales 00:04:31 – The hidden cardiovascular tool almost nobody trains 00:05:03 – A free physiological capacity already built into your body 00:05:38 – What the science actually says about breath-hold training 00:06:09 – Understanding the mammalian dive response 00:06:37 – Your heart, blood vessels, and spleen react within seconds 00:07:11 – Your spleen is a biological oxygen reservoir 00:08:05 – Sponsor: Manna Vitality 00:09:59 – Why cold water amplifies the dive response 00:10:07 – The extraordinary physiology of Southeast Asian sea nomads 00:10:39 – Humans performing underwater like marine mammals 00:11:14 – The mammalian dive response is trainable 00:11:54 – What happened when elite divers reached extremely low blood oxygen 00:12:30 – How the heart adapts during extreme breath holds 00:13:08 – Cardiac hypoxic resistance and a stronger trained heart 00:13:55 – The important limitations of the current research 00:14:41 – Why breath holding alone isn't a miracle 00:15:09 – Combining hypoxic stress with resistance exercise 00:15:42 – Breath holding as a multiplier, not a replacement 00:16:33 – Practical takeaways for training the dive response 00:17:48 – Final thoughts and closing Thank You to Our Sponsors Alkemis: Go to https://alkemispaint.com/ and use code DARIN10 for 10% off your order. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order. Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "You already have an ancient cardiovascular survival mechanism built into your body. Breath holding can trigger measurable changes in heart rate, blood flow, oxygen availability, and the body's response to hypoxic stress—and with training, that response appears capable of adapting. The goal isn't to treat breath holding like a miracle hack. It's to recognize it as another powerful physiological tool that may become even more effective when intelligently combined with movement and training. Bibliography/Sources Hypoxic Training & Cardiovascular Adaptation Bosco, G., et al. (2021). Effect of apnea-induced hypoxia on cardiovascular adaptation and circulating biomarkers of oxidative stress in elite breath-hold divers. Frontiers in Physiology . https://pmc.ncbi.nlm.nih.gov/articles/PMC8458773/ Combined training in hypoxic environments improves cardiometabolic health in older adults: A systematic review and meta-analysis of randomized controlled trials. (2025). Frontiers in Medicine . https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1728637/full Costalat, G., et al. (2021). Physiology, pathophysiology and (mal)adaptations to chronic apnoeic training: A state-of-the-art review. European Journal of Applied Physiology, 121, 2669–2685 . https://link.springer.com/article/10.1007/s00421-021-04664-x Palada, I., Bakovic, D., Valic, Z., et al. (2007). Cardiovascular regulation during apnea in elite divers. Hypertension, 50(2) . https://www.ahajournals.org/doi/10.1161/hypertensionaha.108.127530 Patrizio, I., et al. (2021). Cardiac hypoxic resistance and decreasing lactate during maximum apnea in elite breath-hold divers. Scientific Reports, 11, 3676 . https://www.nature.com/articles/s41598-021-81797-1 The Mammalian Dive Reflex & Genetic Adaptations Ilardo, M. A., Moltke, I., Korneliussen, T. S., et al. (2018). Physiological and genetic adaptations to diving in sea nomads. Cell, 173(3), 569–580 . https://news.berkeley.edu/2018/04/19/enlarged-spleen-key-to-diving-endurance-of-sea-nomads/ Schagatay, E. (2000). Studies on trained apnea divers' amplification of the diving response. Mid Sweden University . https://freedivecafe.com/2019/06/04/42-transcript-erika-schagatay-the-science-of-freediving/ Speck, D. F., & Bruce, D. S. (1978). Effects of varying thermal and apneic conditions on the human diving reflex. Undersea Biomedical Research . https://www.scientificamerican.com/article/breath-holding-dive-reflex-extends/ Inspiratory Muscle Strength Training (IMST) Craighead, D. H., Heinbockel, T. C., Freeberg, K. A., et al. (2021). Time-efficient inspiratory muscle strength training lowers blood pressure and improves endothelial function, NO bioavailability, and oxidative stress in midlife/older adults with above-normal blood pressure. Journal of the American Heart Association, 10(13) . https://www.ahajournals.org/doi/10.1161/JAHA.121.022203

In this episode of the Medical Sales Podcast, host Samuel Adeyinka sits down with Jaymen McClain, a Senior Cardiac Rhythm Management Sales Rep at Medtronic, to take listeners inside the fast-paced world of cardiac medical device sales. Jaymen shares what a typical day looks like, from supporting pacemaker and ICD implants to working alongside electrophysiologists and cardiologists, managing a team of clinical specialists, and responding to urgent cases. He also breaks down how to build trust with physicians, win business against long-standing competitors, become a valuable resource in the procedure room, and navigate the unpredictable on-call lifestyle. Jaymen also discusses compensation, career growth, burnout, work-life balance, and the persistence it took to transition from pharmaceutical sales into medical devices. This episode is a must listen for anyone considering a career in cardiac medical device sales or looking to become a top-performing medical sales rep. Connect with Jaymen McClain: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

On today's show we get into the Cubs and White Sox series, and how the White Sox have become a rollercoaster team. We then get into Bears pre season and how has impressed. Later Max Strus joins the show to talk about his growth in the NBA from Depaul, and how it feels knowing you may be getting traded. SUPPORT THE SHOW Modelo - Stock Up Now https://www.modelousa.com/pages/product-locator?utm_source=BarstoolSports&utm_medium=Streaming-Audio&utm_keyword=3P-MULT&utm_campaign=FY27ModeloEspecialEquityEL&modelId=080660957579 NOBULL - Visit https://www.nobullproject.com and use code STRETCH for 35% off your entire FIRST order Mountain Dew - Enjoy the refreshing citrus kick of Mountain Dew: an American Original. Grab a Dew. Tasting Great Since 48.You can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/redlineradio

Contributor: Taylor Lynch, MD Educational Pearls:  CPR is an important life-saving measure designed for anyone to perform. Chest compressions works by two mechanisms:  Cardiac pump: Direct squeezing of the heart Thoracic pump: Increasing intrathoracic pressure, causing increased blood flow Proper hand placement per current AHA guidelines:  Hands are placed in the center of the chest, on the lower half of the sternum A recent study challenged this approach, using TEE during chest compressions to visualize the cardiac structures being compressed. They found that when hands were placed ~1cm to the left of the sternum, this compressed the left ventricular outflow tract, potentially restricting forward blood flow. Hand placement ~4cm to the left of the sternum resulted in more effective compression of the left ventricle. While this is not yet reflected in AHA guidelines, the study presents an interesting finding that may influence how CPR is performed in the future.  Key takeaway: Always prioritize administering high quality compressions. References:  American Heart Association. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(23_suppl_1). doi:10.1161/CIR.0000000000001378. Chu S, Cheng C, Chang C, et al. Transesophageal echocardiography during CPR in patients with out-of-hospital cardiac arrest: the EXECT-CPR randomized clinical trial. JAMA Intern Med. 2026;186(5):557-566. doi:10.1001/jamainternmed.2026.0102.   Summarized by Ashley Lyons, OMS4 | Edited by Ashley Lyons & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

LISTENER DISCRETION IS ADVISED!!! References: Evans C, Quinlan DO, Engels PT, Sherbino J. Reanimating Patients After Traumatic Cardiac Arrest: A Practical Approach Informed by Best Evidence. Emerg Med Clin North Am. 2018 Feb;36(1):19-40. Lott, C., Truhlář, A., et al. (2021). European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances. Resuscitation, 161, 152-219. Reuben Strayer's ATLS Lecture at ResusX: https://youtube.be/OwgYKtB2Kj0?si=4YFkJ4oPB4l3VEGC Zaf Quasim/Haney Mallemat Critical Care Now Podcast link: https://www.youtube.com/watch?v=HePF-mEtvOc

CardioNerds (Dr. Apoorva Gangavelli, Dr. Cory Sejo, and Dr. Joseph Kassab), discuss tricuspid regurgitation evaluation and management with Dr. Sunil Mankad. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course.  Audio editing by CardioNerds intern Emma Winakur. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Key Points: Tricuspid regurgitation is common and associated with increased mortality at every stage, regardless of etiology. Outcomes are worse with worsening severity, so accurate grading is critical. Etiology is critical to guide treatment decisions. Etiology includes primary vs secondary (atrial or ventricular) vs CIED-related TR. 3D echocardiography can be very helpful in determining TR etiology, especially in CIED-related TR. Diuresis with the goal of euvolemia is step one. Additionally, underlying contributory conditions (eg. pulmonary HTN, HFrEF, atrial fibrillation) should be addressed, if appropriate, and then TR severity reassessed. The choice between T-TEER and TTVR hinges on anatomy, RV function, pulmonary hypertension, and the ability to tolerate anticoagulation. T-TEER is generally first line in atrial functional TR with appropriate anatomy, in patients with poor RV function who cannot tolerate a sudden increase in RV afterload, or in patients who cannot tolerate the necessary anticoagulation with TTVR. TTVR is preferred with wide coaptation gaps and CIED-related TR. This is a team sport. Multidisciplinary discussions utilizing imaging (TTE/TEE, CT), risk scores (TRI-SCORE or TRIO), patient preference, and prior institutional experience are essential for the effective treatment of severe TR. Notes: What is the clinical importance of tricuspid regurgitation? TR is very common with approximately 4% of people over 75 having moderate or greater severity. TR (even mild) is associated with increased mortality. Those outcomes worsen as the TR severity worsens, and this phenomenon is independent of the mechanism of regurgitation. What is unique about the tricuspid valve compared to the other cardiac valves? It is at an anterior location which allows it to be imaged well with transthoracic echocardiography It is the largest valve and composed generally of 3 leaflets (but very often can have 4+ leaflets). Importantly, the RV is compliant and changes size and shape readily based on loading conditions. The TV annulus similarly changes size and shape based on hemodynamic conditions such as preload. What is a good framework for approaching the causes of tricuspid regurgitation? Determine the presence and define the severity of TR. Using TTE, we want to measure the right atrial size, the RV size, and any other concomitant valvular lesions.  Use TTE (2D and 3D) to characterize leaflet anatomy and characteristics. Subtypes of TR mechanisms (many times etiology is mixed). Primary: primary leaflet abnormality, occurs in ~10% of cases. Look for prolapse, flail, endocarditis, etc. Secondary/functional: leaflets normal but surrounding structures are abnormal. Atrial: RA and tricuspid annular dilation but normal RV size/shape, and can be related to arrhythmias like atrial fibrillation. Ventricular: RV dilated and/or dysfunctional with leaflet tethering. Can be related to pulmonary hypertension or primary RV disease. Cardiac implantable electronic device (CIED): Related to device (usually pacemakers or ICD) interaction with TV leaflets. Includes perforation, entanglement in subvalvular apparatus, impingement, etc. 3D TTE particularly helpful to evaluate How do we grade TR severity? It is very important to grade the severity of TR, and this is generally done with echocardiography. There are both quantitative and qualitative methods which use Doppler and various equations to estimate TR severity. Current recommendations have expanded TR severity beyond mild/moderate/severe to include “massive” and “torrential” categories. The most important parameters measured/calculated are vena contracta width, regurgitant volume, regurgitant fraction, and effective regurgitant orifice area. Helpful qualitative metrics include hepatic venous flow reversal. When should additional studies beyond transthoracic echocardiography, such as transesophageal echocardiography (TEE), cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI) be pursued? TEE is particularly helpful if TTE views are poor. Since TEE is used during transcatheter intervention, a pre-procedure TEE to define anatomy, determine procedure candidacy, and plan for the procedure is critical.  CT is also helpful for procedure planning and has particular strengths in defining annulus size and geometry. A CT is required prior to transcatheter tricuspid valve replacement (TTVR). MRI is helpful for measuring RV volumes and function, but is not generally used to assess TR severity.  What is the approach to the treatment for severe tricuspid regurgitation? The first step is to try to determine the etiology. For secondary TR, treating the underlying condition is indicated. For example, pulmonary vasodilators for pulmonary HTN or guideline therapy for heart failure with reduced ejection fraction. Diuretics are the mainstay for treatment, with the goal to obtain euvolemia. This may require inpatient admission to optimize volume status and medication regimen. Once reversible etiologies are addressed, if the patient is still symptomatic from TR, additional therapies can be considered. What is the role of right heart catheterizations (RHC) in patients with severe TR? RHC is very helpful for many reasons. We use it in TR to help determine volume status, cardiac output, and RV function. Additionally, identifying and characterizing pulmonary hypertension (with pulmonary artery pressures and calculating pulmonary vascular resistance) is an important factor when choosing future therapies.  With severe tricuspid regurgitation, when should we refer for intervention (either with surgery or transcatheter repair or replacement)? Once reversible etiologies are addressed and euvolemia has been achieved, if the patient is still symptomatic from TR despite aggressive medical optimization, additional therapies can be considered. Once euvolemic, a repeat TTE should be ordered to reassess the severity of the TR. Use calculators (for example, either the TRI-SCORE or TRIO score) to predict operative mortality for isolated TR surgery. What are our transcatheter treatment options in severe tricuspid regurgitation, and how do we choose between them? The primary approved transcatheter treatment options for severe TR include transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), of which the Edwards EVOQUE valve is the only one currently approved by the FDA. There are other TTVR device under investigation. These decisions should be made with a multi-disciplinary team including representation from cardiac imaging, interventional cardiology, and cardiothoracic surgery. Factors that go into the decision between T-TEER and TTVR include anatomy (annulus width, coaptation gap, leaflet length), RV reserve, pulmonary hypertension presence, ability to tolerate anticoagulation, patient preference, and institutional experience.  T-TEER is generally the first line with atrial functional and suitable anatomy. It is successful at reducing TR but does not generally eliminate it.  TTVR with EVOQUE is preferred in certain anatomic considerations like a large coaptation gap or when there is CIED-related TR (as this was excluded in T-TEER trials). Patients must be suitable for anticoagulation to receive TTVR as there is risk of leaflet thrombosis without it. If moderate/severe pulmonary hypertension is present, or there is poor RV function, TTVR may be avoided as the sudden elimination of TR causes a sudden increase in RV afterload which may not be tolerated. What is the role in advanced metrics for evaluating RV function? Advanced metrics like RV/PA coupling are under investigation but have not made it into the guidelines. The clinical utility is not yet known.  Assessing the RV function is important as stated above. Dr. Mankad prefers using 3D TTE to calculate an RVEF, or tracking RV longitudinal free wall strain. If you do encounter CIED-related TR, how do you treat it? Evaluate with TTE or TEE. 3D is very helpful to identify relative anatomy and leaflet-device interactions. There is no clear consensus about treatment if CIED-related TR is the primary mechanism of severe TR. If recently implanted, repositioning may be a valid option, but requires discussions with multiple teams including electrophysiology, advanced cardiac imaging, CT surgery, and interventional cardiology. References O’Gara PT, Lindenfeld J, Hahn RT, et al. 10 Issues for the Clinician in Tricuspid Regurgitation Evaluation and Management: 2025 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2025;S0735-1097(25)07047-0. O’Gara PT, Little SH, Badhwar V, et al. Operator and Institutional Recommendations and Requirements for Tricuspid Interventions: 2026 ACC/AHA/ASE/HRS/STS Expert Consensus Systems of Care Document. J Am Coll Cardiol. 2026;S0735-1097(26)05481-1. Hahn RT. Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876-1891. Davidson LJ, Tang GHL, Ho EC, et al. The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association. Circulation. 2024;149(22):e1223-e1238.

In this episode of MedAxiom HeartTalk, host Melanie Lawson, MS speaks with Byron Lee, MD, professor of medicine and cardiology at Stanford, about the growing importance of remote cardiac monitoring in patient care. Dr. Lee shares how extended 30-day monitoring helps improves arrhythmia detection and guides long-term treatment. He also discusses how real-time data transmission and streamlined reporting allow care teams to identify and address serious cardiac events more quickly and confidently.

A clearer heart scan can change more than an image, it can change a decision. We talk with Jared Vest, who oversees nuclear cardiology and PET CT at Centra, about the arrival of cardiac PET CT and why it's a major leap forward for diagnosing heart disease closer to home. We walk through SPECT versus PET in plain language, then dig into what makes PET CT the new gold standard: higher-quality imaging and the CT mapping that helps correct for attenuation artifacts that can mask or mimic poor blood flow. That accuracy matters because it helps clinicians send the right patients to the right next step, including whether someone truly needs a heart cath or can avoid an unnecessary procedure.We also get into what's especially exciting about cardiac PET CT: the ability to quantify blood flow and coronary flow reserve, not just “look” at perfusion. That opens the door to detecting smaller defects and microvascular disease earlier, and it points toward future options like viability imaging to see whether heart muscle can benefit from intervention. If you care about preventive cardiology, advanced cardiac imaging, or patient-centered heart disease care, hit play, then subscribe, share with a friend, and leave us a review with your biggest takeaway.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Cardiac rehabilitation is a personalized, prescribed plan following a cardiac event or surgery that's focused on physical activity, nutrition and stress management. Dr. Zara Babayan, board certified in cardiovascular disease, and Roxany Leon, cardiac rehab supervisor, discuss what patients can expect in cardiac rehab and the many benefits including reduced risk of heart attacks and improved overall wellbeing. Learn more about cardiac rehab at BayCare.

Susan Smith has cardiac Sarcoidosis.  One day she was in spin class, and all of a sudden her life went into a spin.  Sarcoidosis has raised its ugly head, and now she is taking things day by day as she works with her medical team to find a solution to what seems to be a worsening problem. Susan contacted me following the release of the podcast saying she wished she had been more specific with respect to some of her diagnosis.  She asked me to pass along the following information: I wish I had made clear that I am being evaluated for autonomic small fiber neuropathy and my symptoms not only include weird sensations in the feet, dry eyes, and body temperature dysregulation but also bloatedness after eating and drinking, cold intolerance in my fingers and toes and sexual dysfunction.    Also, I wish I had explained more about how it was evident to me that I had cardiac sarcoidosis before getting the results of my first PET and my first cardiac MRI. I had had two 30 minute long episodes of ventricular tachycardia, a month apart. The second one came after being loaded up with Amiodarone at the hospital and beginning a daily dosage at home. Amiodarone is the most potent anti-arrhythmia drug available. The second episode of ventricular tachycardia did not result in my ICD firing because the Amiodarone had dampened the v-tach, making the heart beat less fast. The settings on my ICD were for a higher grade v-tach. The ER doctor shocked my heart back into rhythm. I remember it well because he did not sedate me. After the second prolonged v-tach, my primary cardiologist said to me that there must be “Infiltrations” in my heart. He threw out the word “sarcoidosis.” I read about cardiac sarcoidosis and compared my symptoms to those associated with other cardiomyopathies. It seemed to me that it was highly likely that I had cardiac sarcoidosis.    Show notes:   Johns Hopkins Sarcoidosis Event: https://aspire.hopkinsmedicine.org/project/49528 FSR helps patients navigate insurance:  https://www.stopsarcoidosis.org/foundation-for-sarcoidosis-research-announces-new-partnership-with-patient-advocate-foundation-to-expand-insurance-and-disability-support-for-sarcoidosis-patients/ Sarcoidosis News Pulmonary relapse report: https://sarcoidosisnews.com/news/relapse-common-pulmonary-sarcoidosis-treatment-changes/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #kidney #dermatology #cardiacsaroidosis                      

Send us Fan MailA dog needs a pacemaker, the estimate is five figures, and the family's last lifeline is a GoFundMe link. We wanted to know what happens next when veterinary teams suggest crowdfunding as a way to cover the cost of canine pacemaker implantation and whether it truly works often enough to be responsible advice.We sit down with cardiologist and researcher Dr. Mark Rishniw to break down what he found by mining publicly available GoFundMe campaigns for dog pacemakers. We talk about how “success” gets defined, why reaching 80% of a target can still be a huge gap, and the uncomfortable headline: only a small slice of campaigns come close, while many never reach even half of what they ask for and some raise nothing at all. We also explore a pattern that changes the timeline for decision-making, with most donations arriving early and then fading fast.From there, we widen the lens to the rising cost of advanced veterinary procedures, the reality that some interventions now rival the price of a car, and what that means for client conversations when the choices feel like treatment or euthanasia. We also discuss where pet insurance fits, why “friends and family” may be the true engine of most fundraising, and how to set expectations without taking hope away.If you've ever wondered what to tell a client considering veterinary crowdfunding, this one will give you data and language you can use. Subscribe, share this with your team, and leave us a rating and review on Apple Podcasts or wherever you listen.JAVMA article: https://doi.org/10.2460/javma.26.03.0160INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ®  OR AJVR ® ?JAVMA ® : https://avma.org/JAVMAAuthorsAJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® :Facebook: Journal of the American Veterinary Medical Association - JAVMA | FacebookInstagram: JAVMA (@avma_javma) • Instagram photos and videosTwitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | FacebookInstagram: AJVR (@ajvroa) • Instagram photos and videosTwitter: AJVR (@AJVROA) / TwitterJAVMA ®  and AJVR ®  LinkedIn: https://linkedin.com/company/avma-journals

Send Zorba a message!Zorba opens up about his recent surgery, and what led to it. He helps a caller with a question about dealing with AI on health websites. He gives advice to a listener regarding liver health, discusses why the PSA test for prostate health is seen as controversial, and we hear from the pesky Grammar Cops.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba opens up about his recent surgery, and what led to it. He helps a caller with a question about dealing with AI on health websites. He gives advice to a listener regarding liver health, discusses why the PSA test for prostate health is seen as controversial, and we hear from the pesky Grammar Cops.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Ingar Ziad Restan, Yong Yong Tew, Ole-Thomas Steiro, Ziwen Li, Hilde L Tjora, Jørund Langørgen, Torbjørn Omland, Paul Collinson, Rune Bjørneklett, Kjell Vikenes, Trude Steinsvik, Øyvind Skadberg, Øistein R Mjelva, Alf Inge Larsen, Vernon V S Bonarjee, Nicholas L Mills, Kristin M Aakre. Exploring Sex-Specific High-Sensitivity Cardiac Troponin Thresholds for Rule-Out of Non-ST-Elevation Myocardial Infarction. Clinical Chemistry, Volume 72, Issue 8, August 2026, Pages 868–879. https://doi.org/10.1093/clinchem/hvag030

You feel anxious. Nothing has happened. Nothing is wrong on paper. Dr. Aimie learned in the emergency room that anxiety is never one thing. Someone would come in and say the word, and her job was to work out why. It could be a hard week. It could be a heart attack. Same word, two entirely different bodies. She still runs that checklist on herself. Then she read Dr. Nicole Cain's book Panic Proof and found the same approach mapped into nine types, each one named for the body system driving it. In this Part 1 conversation, they cover the first three. Cardiac, gut, and thought anxiety. You will learn how to tell fear from anxiety from panic, why the first place you feel it is your best clue, and why the same word describes both high energy activation and shutdown. This is Part 1 of two.    WHAT YOU'LL LEARN: 03:15 Why anxiety gets treated as one condition 06:33 Fear, anxiety, and panic as three different states 08:07 The green, yellow, and red zones 09:31 How your body measures how much danger you are in 11:08 Your canary, and why the first signal matters 12:25 High energy anxiety or shutdown 13:27 Flop, fawn, fracture, and perimenopause 15:24 The therapeutic order 17:09 Cardiac anxiety, and when to see a cardiologist 19:28 Gut anxiety and the gut-brain axis 21:11 What a food and mood journal revealed 22:34 Thought anxiety and looping thoughts 25:07 Parts work, and the moment it landed for Miguel RESOURCES: Get the free guide, Is It Stress or Trauma? For working out whether what you carry is ordinary stress, or something past that line. Get The Biology of Trauma book. Read Chapter 3, on our critical line and our capacity. It covers how the body reads danger. Panic Proof by Dr. Nicole Cain Dr. Nicole Cain's website Full show notes:  This episode includes a personal disclosure about thoughts of suicide connected to a food reaction. Content here is educational and is not medical advice.

8/4/2026 | Cardiac

Cardiac arrest remains one of the most scrutinised and resource-intensive presentations in prehospital care. We invest heavily in improving what happens in the moment, compression quality, airway strategies, defibrillation timing, and team coordination. Yet one of the most powerful determinants of system performance often sits outside the resuscitation itself: what we do with the data afterwards.In many services, once the patient is handed over or resuscitation is terminated, the process effectively stops. Information is fragmented, device data is reviewed inconsistently, and structured debriefing is applied variably. As a result, opportunities to identify system errors, reinforce high performance, and drive meaningful quality improvement are frequently lost.At the same time, prehospital systems are generating more data than ever before CPR metrics, rhythm timelines, drug administration logs, and physiologic trends. The challenge is no longer collection, but conversion: turning raw resuscitation data into actionable learning. Layered on top of this is an emerging opportunity to deliver meaningful information to hospitals in real time, supporting earlier decision-making in the ED and cath lab before the patient even arrives.In this episode, we explore how structured debriefing, post-arrest analysis, and improved data integration could transform cardiac arrest care from a series of isolated events into a continuous learning system spanning prehospital teams and receiving hospitals.This episode is sponsored by PAX: The gold standard in emergency response bags.When you're working under pressure, your kit needs to be dependable, tough, and intuitive. That's exactly what you get with PAX. Every bag is handcrafted by expert tailors who understand the demands of pre-hospital care. From the high-tech, skin-friendly, and environmentally responsible materials to the cutting-edge welding process that reduces seams and makes cleaning easier, PAX puts performance first. They've partnered with 3M to perfect reflective surfaces for better visibility, and the bright grey interior makes finding gear fast and effortless, even in low light. With over 200 designs, PAX bags are made to suit your role, needs, and environment. And thanks to their modular system, many bags work seamlessly together, no matter the setup.PAX doesn't chase trends. Their designs stay consistent, so once you know one, you know them all. And if your bag ever takes a beating? Their in-house repair team will bring it back to life.PAX – built to perform, made to last.Learn more at ⁠https://www.pax-bags.com/en/⁠

Dr. Philip Ovadia, MD, is a board-certified heart surgeon who became a leading advocate for metabolic health after confronting both his patients' outcomes and his own struggle with obesity and insulin resistance. With decades of surgical experience, he has witnessed firsthand the consequences of metabolic disease. Today, he focuses on prevention, education, and empowering individuals to reverse metabolic dysfunction before surgery becomes necessary. Founder of Ovadia Heart Health and host of The Stay Off My Operating Table Podcast. BUY THE BOOK!  Stay Off My Kitchen Table can be purchased here: https://stayoffmykitchentable.com/ Instagram: https://www.instagram.com/ifixhearts/ Facebook: https://www.facebook.com/ifixhearts YouTube: https://www.youtube.com/@UCu8xppo0Y7mJz4uqkc7o7TQ  Apple Podcasts: https://podcasts.apple.com/ca/podcast/stay-off-my-operating-table/id1587212660 Timestamps: 00:00 Trailer 01:11 Introduction 03:27 Interest in cardiac surgery and metabolic health 07:35 Healthcare system restrictions on doctors 12:31 Cardiac diet and post-surgery care 15:28 Book release and diet exploration 19:54 Moving to Florida and health insights 22:53 Controversial PCSK9 trial results 26:09 Challenges in understanding cholesterol 30:19 Discussing heart disease diagnoses 31:33 Importance of arterial plaque screening 37:26 Heart attacks and undiagnosed diabetes 39:13 Understanding CAC score progression 44:38 Discussing blood pressure guidelines 46:40 Where to find Dr. Ovadia Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Ethan Pratt, Head of Engineering at SandboxAQ's AQMed division, joins Tai-Danae Bradley for a conversation about building heart-health technology that can meet clinicians where they are: in the fast, messy reality of the emergency room.In this episode, Ethan explains AQMed's work on magnetocardiography, a technique designed to capture the heart's magnetic signals and help address one of medicine's toughest everyday challenges: evaluating chest-pain patients in the ER's diagnostic “gray zone.” He shares why the team has focused so intensely on real hospital workflows, how an “algorithmic shield” helps separate the heart's signal from ambient magnetic noise, and why getting prototypes into real clinical settings matters more than waiting for perfection in the lab.The conversation also traces Ethan's unconventional path into medtech, from rebuilding a 1967 Camaro and studying physics at Cal Poly to earning a PhD at Cornell and eventually discovering that his strengths lay not in abstract theory alone, but in building experiments, devices, and teams that work in the real world. Along the way, he reflects on math anxiety, interdisciplinary collaboration, and the guiding principle that has shaped both his career and his leadership style: start with what you know.CAUTION— CardiAQ is an investigational device. Limited by Federal (or United States) law to investigational use.LinksLearn more about SandboxAQ's AQMed team here: https://www.sandboxaq.com/solutions/aqmed Connect with Ethan on LinkedIn: https://www.linkedin.com/in/ethanpratt/ About this podcastThis podcast is hosted by Tai-Danae Bradley and features the stories of amazing people working in science and technology at SandboxAQ and beyond. All curious humans are invited to join!Want to get in touch? Write us at faq-podcast@sandboxaq.comFor previous episodes, check out https://www.youtube.com/@sandboxaq

Scott Coleman and Stephen Tolbert discuss three wild games in Baltimore over the weekend, capped off by a wacky 11th inning win on Sunday to improve the Braves to 7-3 in the second half. The boys also discuss the nearing trade deadline, a fatigued bullpen, Ronald Acuña Jr.'s pending return, and much more.

Tony Haskel is fighting cardiac sarcoidosis.  He has been battling the disease since 2022, and it's been a long road back.  In fact, he will tell you he's nowhere close to where he once was or where he wants to be.  Tony is a return visitor to the podcast, having first joined me in March of 2023.  We both felt like it was time for an update.   SHOW NOTES FSR helps patients navigate insurance:  https://www.stopsarcoidosis.org/foundation-for-sarcoidosis-research-announces-new-partnership-with-patient-advocate-foundation-to-expand-insurance-and-disability-support-for-sarcoidosis-patients/    Sarcoidosis News Pulmonary relapse report: https://sarcoidosisnews.com/news/relapse-common-pulmonary-sarcoidosis-treatment-changes/ John's story from the White House on Col. John Ripley: https://www.wsls.com/video/news/2026/06/19/col-john-ripley-of-radford-receives-posthumous-medal-of-honor/   MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #kidney #dermatology                

In this bonus episode, Dr. Kahn interviews functional medicine specialist Ivan Rusilko about the importance of advanced lab panels. Together, they explore the full spectrum of cardiac lab testing, with a special focus on inflammation, insulin resistance, and how these markers can uncover hidden cardiovascular risk. If you are a health care practitioner, set up an account at accessmedlab.com. Mention the Heart Doc VIP Podcast when creating your new practitioner account to receive 50% off CardioPro™ Advanced Diagnostic Panels, providing unparalleled insights into patient health.

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

Contributor; Taylor Lynch, MD Educational Pearls: Thoracotomy  Thoracotomy is used in traumatic cardiac arrest to replace conventional CPR with direct access to the chest. Goals include identifying and controlling reversible causes of bleeding, prioritizing blood flow to the heart and brain, and performing open cardiac massage. Trauma categories Penetrating trauma: Gunshot wounds and stab wounds. Has a higher chance of survival because the injury may be localized and directly repairable. Cardiac stab wounds may have the highest survivability because the defect can be visualized, repaired, and treated with blood administration. Blunt trauma: Motor vehicle collisions and falls from height. Has a much lower chance of survival. Western guidelines EMS must witness the patient lose pulses. Penetrating trauma: CPR for less than 15 minutes. Blunt trauma: CPR for less than 10 minutes. Survival decreases to essentially zero beyond these time limits. Eastern guidelines Focus on the presence of signs of life in blunt or penetrating trauma. Signs of life may include: Pupillary response. Measurable blood pressure. Purposeful movement. Patient selection Thoracotomy should only be performed when the patient has a reasonable chance of survival. It is a highly morbid procedure with significant occupational risks, including needlestick injury. Appropriate patient selection and timing are essential. Procedure Begin on the left side of the chest. Cross-clamp the aorta to restrict blood flow below the heart and prioritize circulation to the heart and brain. Identify and repair visible sources of bleeding involving structures such as the heart or lungs. Perform open cardiac massage as the equivalent of CPR. ACLS medications may still be administered. References: Cothren CC, Moore EE. Emergency department thoracotomy for the critically injured patient: Objectives, indications, and outcomes. World J Emerg Surg. 2006;1:4. Published 2006 Mar 24. doi:10.1186/1749-7922-1-4 Rhee, Peter M. ; Acosta, Jose ; Bridgeman, Amy et al. / Survival after emergency department thoracotomy : Review of published data from the past 25 years. In: Journal of the American College of Surgeons. 2000 ; Vol. 190, No. 3. pp. 288-298. Nunn, Andrew ; Prakash, Priya ; Inaba, Kenji et al. / Occupational exposure during emergency department thoracotomy : A prospective, multi-institution study. In: Journal of Trauma and Acute Care Surgery. 2018 ; Vol. 85, No. 1. pp. 78-84. Burlew CC, Moore EE, Moore FA, et al. Western Trauma Association critical decisions in trauma: resuscitative thoracotomy. J Trauma Acute Care Surg. 2012;73(6):1359-1363. doi:10.1097/TA.0b013e318270d2df Seamon MJ, Haut ER, Van Arendonk K, et al. An evidence-based approach to patient selection for emergency department thoracotomy: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2015;79(1):159-173. doi:10.1097/TA.0000000000000648 Summarized by Steven Fujaros NREMT | Edited by Steven Fujaros & Ahmed Abdel-Hafiz, NREMT-P   Donate: https://emergencymedicalminute.org/donate/   Join our mailing list: http://eepurl.com/c9ouHf

In this episode of the Prolonged Field Care Podcast, Dennis sits down with Dr. Andre Cap to unpack the evolving role of calcium in trauma resuscitation. What started as the “new hotness” in forward blood transfusion protocols has become far more nuanced. They discuss the dangers of both hypocalcemia and hypercalcemia, how citrate in all blood products binds ionized calcium, cardiac effects, recent observational data showing worse outcomes with hypercalcemia, and practical guidance for when, how, and how much calcium to give in austere and prolonged field care environments.Whether you're running a Role 2, working prolonged field care, or just trying to keep your patient alive until definitive care, this episode challenges long-held assumptions and offers field-practical recommendations.Key Takeaways:All blood products contain citrate, which binds ionized calcium — expect hypocalcemia with significant transfusion.Both hypo- and hypercalcemia are bad; recent data shows hypercalcemia is associated with worse mortality than hypocalcemia.Current TCCC guidance (1g calcium after first unit) was written to fix under-use; it may now be too aggressive in some scenarios.Give calcium after blood products, not before. Consider waiting until after 2+ units in most cases.Slow IV push (over ~5 minutes) through a confirmed good peripheral line; calcium chloride is a vesicant — use caution (gluconate is safer).Avoid calcium chloride via IO if possible. Titrate to clinical response when monitoring isn't available.In refractory shock you can give more, but don't give calcium as a standalone resuscitation drug — it can be harmful without volume replacement.Ideal future state: Bring i-STAT capability forward when feasible and get better RCT data.Perfect for medics, PAs, physicians, and anyone managing hemorrhagic shock in austere environments.Links:⁠www.prolongedfieldcare.org⁠ | @prolonged_field_carePodcast Chapters (with Timestamps):00:00 – Intro & Welcome00:39 – Why Calcium Became “The New Hotness” in Trauma Care01:18 – The Joint Trauma System Audit That Started It All03:46 – Citrate in Every Blood Product – The Science Behind the Bind05:44 – Why We Actually Care: Cardiac Repolarization, Contractility & Vascular Tone08:49 – Hypocalcemia vs Hypercalcemia in Trauma Patients10:21 – Shocking New Data: Hypercalcemia Carries Higher Mortality13:14 – TCCC Guidelines – After First Unit? Is This Too Aggressive?14:03 – When Should You Actually Give Calcium in the Field?19:34 – Clinical Triggers Without Monitoring + Dosing Strategy24:56 – Safety First: IV Patency, Calcium Chloride vs Gluconate, IO Concerns28:44 – When to Stop Giving Calcium & Avoiding Over-Correction32:00 – Historical Lessons: When Calcium Alone Made Things Worse33:39 – Practical PFC Recommendations & Final Thoughts38:04 – Closing & Where to Find MoreFor more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠⁠⁠

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/NKC865. NCPD credit will be available until July 23, 2027.Winning Strategies for Managing Transthyretin Cardiac Amyloidosis: The Heart Failure Nurse's Game Plan In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Broadcast from KSQD, Santa Cruz on 7-16-2026: Dr. Dawn dissects a June 2026 JAMA Internal Medicine paper that claimed simultaneous flu and COVID vaccination in veterans reduced cardiac events, arguing the retrospective natural-experiment design cannot support causal conclusions. The 20% versus 2% dropout rates between groups signal fundamentally non-comparable populations, and the divergence in cardiac events starting within a month of vaccination is clinically implausible—suggesting an X-factor other than vaccine effect is driving the numbers. Dr. Dawn delivers a pointed critique of a major chain pharmacy—part of a vertical healthcare monopoly—for creating deliberate friction around controlled-substance prescriptions through claims of stock shortages, unnecessary prior authorizations, and phantom "clarification" requests. She acknowledges the real paperwork burden of DEA compliance (quarterly reporting, six-month inspections, legitimate-need documentation) but argues chains are pushing pain patients away rather than doing due diligence, while independent pharmacies are closing at alarming rates in California. Following up on last week's Kampo medicine caller, Dr. Dawn reports research on Goshajinkigan showing it suppresses voltage-gated sodium channels at the motor end plate, functioning as a muscle relaxant used clinically in Japan for low back pain, extremity numbness, and chemotherapy- and diabetic-induced neuropathy. An emailer asks about a case report of an 80-year-old woman with 10-year Alzheimer's whose function dramatically improved after 5g oral psilocybin (Enigma strain), regaining conversation, continence, and autonomous dressing. Dr. Dawn notes plausible mechanisms (neuroplasticity, anti-inflammatory action, elevated BDNF) but cautions the diagnosis was clinical rather than confirmed with imaging or CSF markers, and recommends the emailer pursue exercise and sleep optimization for word-finding difficulties instead. An emailer asks how to reassure her chemically-hypersensitive adult son that their remediated apartment is safe. Dr. Dawn recommends commercial ERMI (Environmental Relative Moldiness Index) testing along baseboards where spores concentrate, plus urine mycotoxin testing on the parents themselves to demonstrate objectively low exposure levels. Drosophila fruit-fly males produce sperm longer than their own 2mm bodies—40 times longer than human sperm—with thousands packed inside. Fluorescent-dye imaging shows the sperm remain unusually still and coordinated, moving in synchronized slow waves like flocking birds or kelp in tides, preventing tangling. A Washington University study of 154,000 UK and 10,000 US participants used nine blood biomarkers to calculate biological age, finding people born in the 1990s show accelerated biological aging compared to those born three decades earlier. The gap between biological and chronological age correlated with increased risk of lung, colon, and uterine cancers—all rising in younger populations. A University of Pennsylvania study of 493 mouse litters found germ-free mice had shorter reproductive lifespans, more ovarian scarring, and accelerated loss of primordial follicles. Introducing gut bacteria at birth or weaning reversed these effects, as did supplementation with short-chain fatty acids alone (butyrate, isobutyrate, acetate). Dr. Dawn suggests ghee as a readily available butyrate source for those interested in the theoretical fertility-preservation benefit.

Dr. Adam Brockman sits down with functional medicine and wellness-tech expert Dr. Dave Heitmann to unpack a landmark shift in cardiovascular care — from a $10 billion acquisition reshaping the wearable- tech landscape to an FDA-cleared wrist device tracking your heart's every beat and movement in real time. They break down what continuous cardiac monitoring actually means for the "normal lab lie" how AI is reshaping who interprets your health data, and what it could mean for the millions of Americans one heartbeat away from a warning sign they'd otherwise never catch in time.

The long run is a staple of training plans from the 5K to ultra - but why? In this episode, we discuss the science of long runs, including the physiological adaptations, progressions, specificity and more. Plus, we answer your questions about why sleep is difficult after a long run, if walk breaks are okay, and if you treadmill long runs at a lower heart rate are better than outdoors.Thank you to our sponsors:✨ Mizuno: Shop Mizuno's newest bouncy supertrainer: https://runtothefinish.com/neovista3/In this episode, you'll learn:✅ Why long runs are beneficial✅ If fueling your long runs compromises adaptations✅ How to progress your long runs✅ How often you should do long runs at goal race pace✅ Cardiac drift, cadence, and other things to pay attention to on long runs✅ Terrain specificity during long runsIf you enjoyed this episode, you may like:

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

On this episode of MedAxiom HeartTalk, host Melanie Lawson, MS sits down with April Mann, MBA, CNMT, NCT, RT(N), MASNC, FSNMMI-TS, stakeholder engagement lead at GE HealthCare. Together, they discuss a collaborative two-part webinar series establishing shared cardiac PET services. Learn about operational, technical, and business case considerations for building a sustainable program. Expert insights will guide administrators and leadership through governance, accountability, and overcoming common challenges in shared service models.

This week we delve again into the world of adult congenital heart disease and specifically the realm of biomarkers when we review a recent report of the proteomics of the adult Fontan patient. What is proteomics and how can this inform our understanding of the pathophysiology and adaptive pathways of the Fontan circulation? Are there meaningful differences in the patterns of protein expression between the adult Fontan patient and control 2 ventricle subjects? What might account for differences and how can we understand these differences to explain outcomes in the Fontan adult patient? We speak with the first and senior authors of this week's work, Professor Alexander Opotowsky of the University of Cincinnati and Mr. Ismael Assi who is a Sarnoff Fellow and soon to be 4th year medical student at the University of Cincinnati. DOI: 10.1016/j.jacadv.2026.102810 

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week we're joined by Kendra Cunningham and Kayla Messana, sisters and co-hosts of the podcast Flatlined and Fine, and their stories are almost impossible to believe. Kayla was 31, healthy, three kids, husband just back from deployment, when she woke him up with agonal breathing in the middle of the night. He dragged her to the floor, did CPR for 10 minutes, and she was shocked twice by an AED before going on to have cardiac arrest approximately eight more times in the next 24 hours. Four years later, she's been shocked by her ICD three additional times and still has no clear diagnosis. Then, a few years after Kayla's event, Kendra had her own cardiac arrest while awake and feeding her newborn twins, told her husband she was about to faint, and was gone within seconds, saved by a man whose only CPR training was a few American Heart Association videos he'd watched before their first child was born. Kristin and I swap notes with them on everything: what it's like to wake up in an ICU with no memory of what happened, how you explain cardiac arrest to kids who are five, six, and eight years old, the psychological weight of an idiopathic diagnosis that gives you no answers and no closure, and the very real experience of being a 31-year-old in a cardiology waiting room surrounded by people forty years older than you. We also get into the insurance disaster of a $15,000 whole exome sequencing test that Blue Cross Anthem denied, why Kendra couldn't pick up her newborn twins for months after her ICD surgery, and why I was cleared to perform eye surgery but not allowed to drive for six months. I also get publicly shamed for not having plugged in my ICD data transmitter in two years. It's earned. Takeaways: Cardiac arrest in young, healthy adults often has no identifiable cause. CPR saves lives even when the person doing it is terrified and untrained. The co-survivor experience is its own separate, underserved story. Young cardiac arrest survivors often get inadequate guidance from the healthcare system. Being shocked by an ICD is traumatic and disruptive in ways that don't get talked about enough. — Want more Kendra Cunningham and Kayla Messana? @flatlined.and.fine on Instagram Flatlined and Fine on Spotify: https://open.spotify.com/show/2nRXIK5OvgAv2CXKvCwrQu?si=eHV4s_CZTQyLAXLvf7A14A&nd=1&dlsi=359ec698e7c64c90 To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: https://glaucomflecken.com/glauc-to-me/ If you are interested in buying a book from one of our guests, check them all out here: https://www.amazon.com/shop/dr.glaucomflecken If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: https://anatomywarehouse.com/?aff=14 Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information. Head to http://www.cozyearth.com and use my code KNOCKKNOCK for an exclusive 20% off. Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Cardiac imaging expert Kim Mischo spent 20 years inside the cardiology machine — running nuclear stress tests that told patients they were fine, then watching some of those patients have heart attacks the following week. She knew the system was broken long before she could prove it.Now she can prove it.A non-invasive scan exists that can detect coronary artery disease at 5% blockage — before symptoms, before a stress test would ever flag anything. It's been guideline-recommended since 2021. It's 99% accurate. And insurance won't cover it.The reason why is the part of this conversation that will stay with you.Dr. Philip Ovadia and Kim Mischo walk through the technology, the economics, and the quiet institutional logic that keeps a life-saving diagnostic tool out of reach for most Americans — while a far less accurate, far more expensive alternative continues to dominate cardiology practices nationwide.This is a conversation about what early detection of heart disease could look like, and why it doesn't yet.BIG IDEABetween 50 and 60 percent of patients die from their first heart attack — which means the insurance company never had to pay a single claim related to their coronary disease.Kim Mischo Contact Info: Website: https://clearheartandlung.com/Send Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com WEBSITE: Stay Off My Kitchen Table Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Ready to take control of your health?  Grab Dr. Ovadia's brand new book Stay Off My Kitchen Table now! This isn't just another diet book; it reveals why it's not just what you eat, but what your body actually absorbs that determines your health.If you're struggling with low energy, stubborn weight, or feeling like “healthy eating” isn't working… this book shows you exactly how to fix it.Learn how to reset your gutEliminate hidden foods sabotaging your progressUnlock real energy, metabolism, and longevityDon't wait until it's too late. Take action today. Get your copy of Stay Off My Kitchen Table now.Learn More:Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart HealthTheme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey (c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

 CardioNerds (Drs. Apoorva Gangavelli, Rebecca Garber, and Tina Reddy discuss INOCA with Dr. Claire Raphael. Audio editing by CardioNerds Academy intern, student doctor Pacey Wetstein. This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli, and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. Non-obstructive coronary artery disease (CAD) is more common than often recognized, particularly in women and individuals with risk factors like diabetes or hypertension. Conditions such as INOCA, ANOCA, and MINOCA can cause ischemia and chest pain despite “clean” angiograms, often due to microvascular dysfunction, coronary spasms, or subtle plaque. Diagnosing these conditions requires advanced imaging or invasive studies to assess blood flow and vessel function. Treatment focuses on reducing cardiovascular risk with aspirin, statins, ACE inhibitors, or ARBs, and managing symptoms with beta-blockers or calcium channel blockers. The key takeaway: A normal angiogram doesn't rule out disease, and these patients need a comprehensive, evidence-based approach to care. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls: When patients present with chest pain but do not have obstructive coronary artery disease, the story does not end there! Other pathologies that must be ruled out include spontaneous coronary artery disease (SCAD), coronary vasospasm, microvascular disease, Takotsubo, and cardiomyopathy. A TTE can help rule out other pathologies. Cardiac MRI can help identify myocardial fibrosis, scarring, or edema that may suggest prior events or alternative diagnoses.  About 60-70% of INOCA cases are in women. However, it is estimated that about half of the patients with so-called “normal” angiograms actually have positive stress tests. Patients with elevated troponins are more likely to have recurrent events. Patients with INOCA are more likely to come back to the ER multiple times before getting diagnosed. These patients have a 1.4x increased risk of adverse cardiovascular events (such as HFpEF, MI, and recurrent hospitalizations for cardiac chest pain).  INOCA is a complex condition with a variety of causes, primarily linked to microvascular disease. Within microvascular disease, there are different “endotypes” (types or subcategories) classified by specific characteristics. In centers that conduct microvascular testing, patients are categorized as endothelium-independent or endothelium-dependent, based on their responses to adenosine or acetylcholine during testing. Additionally, microvascular disease can be classified as either structural or functional, depending on the results of tests measuring microvascular resistance. The field is moving towards the term ANOCA, or angina with non-obstructive coronary arteries, to include patients with anginal symptoms without objective ischemia.  The field is moving toward using genotyping and hemodynamic testing to guide first-line therapies for microvascular disease, a heterogeneous condition. Current treatments mostly come from obstructive coronary artery disease, but specialized approaches—like the coronary sinus reducer—may offer unique benefits for microvascular disease. Treatment includes sublingual nitroglycerin, ACE inhibitors/ARBs, and beta-blockers. Remember to also treat any additional comorbidities, such as diabetes, hypertension, and hyperlipidemia. Unfortunately, many of these patients may still have refractory chest pain, so it is important to reassure them. These patients can still exercise, but they may be hesitant to do so for fear of having chest pain. Cardiac rehab may be helpful for these patients as it helps them build up their tolerance. References Lawton JS, Tamis-Holland JE, Bangalore S, et al; Writing Committee Members. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18-e114. doi:10.1161/CIR.0000000000001039 Hwang D, Park S, Koo B-K. Ischemia with nonobstructive coronary artery disease. JACC: Asia. 2023;3(2):169-180. doi:10.1016/j.jacasi.2023.01.004 Yukselen Z, Majmundar V, Dasari M, Kumar PA, Singh Y. Chest pain risk stratification in the emergency department: current perspectives. Open Access Emerg Med. 2024;16:29-43. doi:10.2147/OAEM.S419657

In this 337th episode I welcome Dr. Andreas Plackis to the show. Dr. Plackis is the creator and host of the TEE Time Podcast and a cardiac anesthesiologist. We talk about TEE for the non-cardiac anesthesiologist, how it can be used and how to go about learning it. Our Sponsors:* Check out BetterHelp and use my code betterhelp.com for a great deal: https://www.betterhelp.com* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor and use my code factormeals.com/accrac50off for a great deal: https://www.factor75.com* Check out Kiwi Biosciences and use my code icaneatagain.com/accrac for a great deal: https://www.kiwibiosciences.com* Check out Quince and use my code quince.com/accrac for a great deal: https://www.quince.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

After losing Monday's opener, the Phillies made MLB history with two incredible 9th inning comebacks against the Washington Nationals in DC. The Good Phight's John Stolnis recaps an incredible week in the nation's capital. So many heroes! Is this team channeling the 2022 NL champs? Also, Justin Klugh joins the show to talk about his book, "Summer of the Cheap Weiners," and Hittin' Season Nationals Insider Ethan Stolnis (yep, they're related).

America Out Loud PULSE with Dr. Peter McCullough and Malcolm Out Loud – Cherry-picked data can be made to say almost anything if the window is narrow enough and the question is framed just right. The public is then handed a reassuring headline while the real safety questions are pushed aside. Bottom line: a fourth COVID-19 booster does NOT protect against cardiovascular events...

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cardiac Tamponade⁠⁠⁠⁠⁠⁠ from the Cardiovascular section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

"Making the effort earlier totally changes the trajectory for the rest of your life,” says Jeremy London, MD. London is a board-certified cardiovascular surgeon with more than 25 years of clinical experience caring for patients across the full spectrum of heart disease — from prevention to advanced intervention. Dr. London received his medical degree from the Medical College of Georgia and completed his general surgery residency at Joseph's Hospital in Denver, Colorado. He completed a general vascular and thoracic surgical fellowship at the Carolinas Medical Center in Charlotte, N.C. To deepen his understanding of medicine, he completed the Institute of Functional Medicine core program. 00:00 - When a cardiac surgeon has a heart attack 10:46 - Waking up with different priorities 13:49 - Missed signals 18:35 - The CGM experiment that revealed pre-diabetes 21:43 - The 5 tests that actually matter 25:44 - Diving into Lp(a) 30:36 - Target numbers for primary prevention 32:26 - Why taking medication isn't failure 38:24 - Atherosclerosis starts in childhood 41:19 - Why a zero calcium score doesn't mean you're safe 45:40 - What we don't know 48:41 - GLP-1s & the future of prevention For more about London, visit his website: https://drjeremylondon.com/  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Is your heart racing? Are you wondering if it's a panic attack or a heart attack? In today's episode of Calming Anxiety, we dive deep into the physiological response of a racing heart due to anxiety. Hosted by Martin Hewlett, a clinical hypnotherapist and former paramedic, this session provides professional insight into why your body triggers the fight or flight response and how to signal to your nervous system that you are safe.If you frequently experience sudden chest tightness, palpitations in your throat, or health anxiety regarding your heart health, this 10-minute guided relaxation and breathing exercise is designed for you. Learn the difference between a medical emergency and an anxiety-driven surge of adrenaline from someone who has seen both on the front lines.What You Will Learn:How to differentiate anxiety symptoms from cardiac emergencies.The role of the parasympathetic nervous system in calming a pounding heart.A guided box breathing technique to lower your heart rate instantly.How adrenaline affects your blood vessels and lungs during stress.Time Chapters00:00 – Emergency Screening: Vital signs of a cardiac event vs. anxiety.01:04 – Introduction: Meet Martin Hewlett, former paramedic and hypnotherapist.01:56 – Guided Breathing: Using the extended out-breath to signal safety.03:38 – The Science of Adrenaline: Why your heart races when you aren't in danger.05:12 – Visualization: The "Control Room" technique for nervous system regulation.07:18 – Affirmations: Rewiring your internal dialogue about heart health.08:32 – 3 Daily Caring Tips: Practical tools for managing heart rate anxiety.10:05 – Closing Thoughts: Embracing your body's natural responses.Heart-Centered AffirmationsRepeat these internally to ground your nervous system:"My heart is strong and it is working exactly as it should"."A racing heart is not proof of danger; it is proof that I am alive and responding"."I know the difference between anxiety and emergency. Anxiety does not require a rescue"."I trust my body to regulate; I trust my breath to lead me home".3 Daily Caring TipsEstablish Your Baseline: Take your resting heart rate on a calm morning to provide a factual reference point for when anxiety spikes.The Physiological Sigh: Use the "double inhale" (two sips of air through the nose) followed by a long, slow exhale to mechanically reset your stress levels.Break the Freeze: Anxiety thrives in stillness. If your heart races, stand up and take three slow, deliberate steps to tell your brain you are not in a "life or death" freeze state.Support the ShowIf this session helped you find a moment of peace, please subscribe to Calming Anxiety on Apple Podcasts. With over 2,300 free episodes, we are here for you every single day.Leave a Review: Your feedback helps others find these tools.Share: Send this episode to a friend struggling with health anxiety.Stay Connected: Visit calminganxiety.fm for more resources.Remember: Smile often, and to your beautiful self, be kind.